plasmacytoma (Cancer)
Information
- Disease name
- plasmacytoma
- Disease ID
- DOID:3721
- Description
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02544308 | Active, not recruiting | Phase 3 | Trial of Immunomodulatory Therapy in High Risk Solitary Bone Plasmacytoma | March 10, 2017 | December 2026 |
| NCT04174196 | Active, not recruiting | Phase 2 | A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma | November 19, 2019 | November 19, 2024 |
| NCT02921893 | Active, not recruiting | Early Phase 1 | Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients With POEMS Syndrome | October 31, 2016 | October 31, 2024 |
| NCT02547662 | Completed | Phase 2 | Pomalidomide, Ixazomib Citrate, and Dexamethasone in Treating Patients With Previously Treated Multiple Myeloma or Plasma Cell Leukemia | December 24, 2015 | October 30, 2020 |
| NCT02506959 | Completed | Phase 2 | Panobinostat, Gemcitabine Hydrochloride, Busulfan, and Melphalan Before Stem Cell Transplant in Treating Patients With Refractory or Relapsed Multiple Myeloma | September 14, 2015 | June 3, 2024 |
| NCT02184533 | Completed | Phase 1 | Sodium Selenite and Radiation Therapy in Treating Patients With Metastatic Cancer | July 2014 | May 2018 |
| NCT00421525 | Completed | Phase 1/Phase 2 | Phase I/II Study of hLL1 in Multiple Myeloma | January 2007 | June 2009 |
| NCT06429150 | Recruiting | Phase 1/Phase 2 | Frontline Combination CAR-T Cell Therapy for Multiple Myeloma or Plasmacytoma | May 11, 2024 | December 31, 2027 |
| NCT03031730 | Recruiting | Phase 1 | Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma | June 14, 2018 | December 31, 2024 |
| NCT03312868 | Terminated | Phase 2 | Stereotactic Body Radiotherapy for the Treatment of Solitary Bone Plasmacytoma | October 1, 2017 | March 28, 2022 |
| NCT00109889 | Terminated | Phase 2 | S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma | April 2005 | April 2007 |
| NCT04065308 | Unknown status | Phase 2 | Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma | January 14, 2019 | September 30, 2021 |
- Disase is a (Disease Ontology)
- DOID:6536
- Cross Reference ID (Disease Ontology)
- ICD10CM:C90.3
- Cross Reference ID (Disease Ontology)
- ICDO:9731/3
- Cross Reference ID (Disease Ontology)
- MESH:D010954
- Cross Reference ID (Disease Ontology)
- NCI:C9349
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:302852008
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0032131
- Exact Synonym (Disease Ontology)
- Myeloma - solitary
- Exact Synonym (Disease Ontology)
- Myeloma, solitary
- Exact Synonym (Disease Ontology)
- Solitary myeloma
- Exact Synonym (Disease Ontology)
- Solitary plasmacytoma
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0011857
- OrphaNumber from OrphaNet (Orphanet)
- 86855
- MeSH unique ID (MeSH (Medical Subject Headings))
- D010954